OOIR: Observatory of International Research

Papers

(The TQCC of Blood Reviews is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Transplant-acquired allergy in HCT-recipients: Reference for clinical management	79
Pitfalls in laboratory monitoring of treatment in people with Haemophilia	78
Editorial Board	73
Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach	72
Radiation and leukaemia: Which leukaemias and what doses?	71
Artificial intelligence in sickle disease	63
Targeting CD38 in immune thrombocytopenia: Rationale and a scoping review of daratumumab	61
Beyond current treatment of Fanconi Anemia: What do advances in cell and gene-based approaches offer?	59
Expanding post-transplant cyclophosphamide to matched unrelated donor transplants and beyond	54
Thalassaemia in China	52
Not all LGL leukemias are created equal	50
Advances in the critical care management for patients with hematological malignancies	48
Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond	47
Targeting the neonatal Fc receptor (FcRn) in hematologic conditions with a focus on warm autoimmune hemolytic anemia	46
Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma	45
Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk	45
Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need	43
Chasing leukemia differentiation through induction therapy, relapse and transplantation	41
Ph-chromosome-negative myeloproliferative neoplasms: clonal dynamics are the name of the game	41
Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103]	36
The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT	35
Adenovirus infection in adult allogeneic hematopoietic stem cell transplant recipients: Systematic review and meta-analysis	35
BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies	33
Breaking down frailty: Assessing vulnerability in acute myeloid leukemia	33
Artificial intelligence in myeloid malignancies: Clinical applications of machine learning in myelodysplastic syndromes and acute myeloid Leukemia	32

Old tests and new paradigms: How to interpret iron studies and related biomarkers for the diagnosis of iron deficiency in adults	32
Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs	32
Harnessing multi-source data for individualized care in Hodgkin Lymphoma	32
Preservation of fertility in female patients with hematologic diseases	31
Clostridioides difficile infection in non-transplanted adults with haematological malignancy: Systematic review and meta-analysis on behalf of European Conference on Infections in Leukemia (ECIL) and	31
Gut microbiome composition and dysbiosis in immune thrombocytopenia: A review of literature	30
Gut dysbiosis, endotoxemia and clotting activation: A dangerous trio for portal vein thrombosis in cirrhosis	29
The acute pain crisis in sickle cell disease: What can be done to improve outcomes?	29
Post-transplantation cyclophosphamide as GVHD prophylaxis in allogenic hematopoietic stem cell transplantation: Recent advances and modification	29
CHIPing away the progression potential of CHIP: A new reality in the making	28
Richter's transformation: Transforming the clinical landscape	27
Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria	27
Current challenges in conditioning regimens for MDS transplantation	27
Down syndrome and leukemia: An insight into the disease biology and current treatment options	25
Metabolomics in sickle cell disease: Current knowledge and gaps – A scoping review	25
Bispecific antibodies in multiple myeloma: maximizing potential through rational combination therapies	25
Editorial Board	24
The mythological chimera and new era of relapse prediction post-transplant	24
Beyond the blood: A practical guide to thalassemia care in the emergency department	24
Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines	24
ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma	23
Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia	22
Addressing the surge of infections by multidrug-resistant Enterobacterales in hematopoietic cell transplantation	22
State-of-the-art review on AL amyloidosis in Western Countries: Epidemiology, health economics, risk assessment and therapeutic management of a rare disease	22
Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?	21
Complementary and alternative medicine for children with sickle cell disease: A systematic review	21
A tale of two sites – Distinct spatial differences between bone marrow and extramedullary AML	21
Optimizing high dose melphalan	21
Αlpha-thalassemia: A practical overview	21
Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists	21
Artificial intelligence applications in thrombotic thrombocytopenic Purpura: A systematic review of diagnostic, risk stratification, and prognostic models	20
Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape	20
Access to CAR T-cell therapy: Focus on diversity, equity and inclusion	20
The role of preoperative transfusion in sickle cell disease, a systematic review and meta-analysis	20
Androgen use in bone marrow failures and myeloid neoplasms: Mechanisms of action and a systematic review of clinical data	19
Long-term durability of rAAV gene therapy in hemophilia: Factor expression, clinical outcomes and underlying molecular mechanisms	19
Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?	19
Navigating acute myeloid leukemia towards better outcomes: Treatment pathways and challenges for patients ineligible for intensive chemotherapy	19
Redefining central nervous system multiple myeloma: From rare phenomenon to emerging entity	19
Bridging the evidence-to-practice gap: Advancing neonatal blood transfusion. A narrative review of recent guidelines	18
The critical role of platelets in venous thromboembolism: Pathogenesis, clinical status, and emerging therapeutic strategies	17
Ven the dose matters: Venetoclax dosing in the frontline treatment of AML	17
Quality of life, mood disorders, and cognitive impairment in adults with β-thalassemia	17
Antibacterial, antifungal and antiviral prophylaxis and vaccination strategies in adult patients with acute myeloid and promyelocytic leukemia: An expert panel consensus from the GIMEMA group	17
A personalized, organ-based approach to the treatment of chronic steroid-refractory graft-versus-host disease	16
Innovations in red blood cell preservation	16
Progress, and prospects in the therapeutic armamentarium of persons with congenital hemophilia. Defining the place for liver-directed gene therapy	16
Tackling myeloma bone disease: From pathophysiology to cutting-edge therapies	16
How do we improve the translation of new evidence into the practice of hematopoietic cell transplantation and cellular therapy?	16
Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment	16